Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MK-1084 by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
MK-1084 is under clinical development by Merck and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
MK-1084 by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
MK-1084 is under clinical development by Merck and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merck's MK-1084?
MK-1084 is a small molecule commercialized by Merck, with a leading Phase III program in Non-Small Cell Lung Cancer. According...